The long term goal of these studies is to define the innate host-virus interactions that occur during hepatitis C virus (HCV) infection with the hope that this will lead to novel therapeutic approaches to this disease. HCV is a noncytopathic, positive-strand RNA virus that causes acute and chronic hepatitis and hepatocellular carcinoma. Approximately 2-4 million persons are chronically infected by HCV in the USA and 170 million people are chronically infected worldwide, many of whom will die from liver failure and hepatocellular carcinoma. The recent development of a robust cell culture model of HCV infection permits analysis of the entire HCV life cycle and facilitates analysis of the host-virus interactions that determine the outcome of HCV infection. Using that model we recently reported that HCV doesn't induce type 1 interferon or interferon stimulated genes in infected cells;that the viral NS3/4A protease blocks double stranded (ds) RNA signaling by cleaving a key intermediate in the dsRNA signaling pathway;and that HCV evades the innate host response in infected cells by an entirely novel NS3/4A-independent mechanism that is mediated by the HCV NS4B protein. We also discovered that type 1 interferon rapidly modulates the expression of a subset of cellular microRNAs (miRNAs) that partially mediate the antiviral effects of IFN against HCV. These findings identify a previously unsuspected effector arm of the interferon response that contributes to the control of HCV infection. In the current proposal we will extend these studies with the following Specific Aims.
In Specific Aim 1, we will characterize the molecular mechanism whereby NS4B blocks double stranded RNA-signaling by determining if it directly interacts with RIG-I, if it regulates RIG-I subcellular localization, and if it blocks the ability of RIG-I to bind dsRNA.
In Specific Aim 2, we will identify the repertoire of cellular miRNAs that mediate the antiviral effect of interferon against HCV, identify the cellular genes that mediate their antiviral effects, and characterize the mechanism whereby those genes control HCV infection. Collectively, these experiments will provide insight into viral evasion and host defense mechanisms that could lead to the development of novel antiviral strategies to terminate chronic HCV infection.
Over 170 million people throughout the world are chronically infected by HCV, 2-4 million of whom live in the United States. Twenty percent of these patients will develop cirrhosis of the liver and about 5% will die from liver failure and cancer. The work described in this proposal will improve our understanding of the biology of this virus with the hope that we will identify vulnerabilities in its life cycle that can be exploited to develop safe and effective antiviral drugs to alleviate the human suffering and socioeconomic burden of this worldwide threat to public health.
|Wieland, Stefan; Makowska, Zuzanna; Campana, Benedetta et al. (2014) Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59:2121-30|
|Wieland, S F; Asabe, S; Engle, R E et al. (2014) Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver. J Virol 88:5184-8|
|Wieland, S F; Takahashi, K; Boyd, B et al. (2014) Human plasmacytoid dendritic cells sense lymphocytic choriomeningitis virus-infected cells in vitro. J Virol 88:752-7|
|Friesland, Martina; Mingorance, Lidia; Chung, Josan et al. (2013) Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol 87:6377-90|
|Giang, Erick; Dorner, Marcus; Prentoe, Jannick C et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109:6205-10|
|MacPherson, Jamie I; Sidders, Ben; Wieland, Stefan et al. (2011) An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection. PLoS One 6:e25584|
|Gastaminza, Pablo; Pitram, Suresh M; Dreux, Marlene et al. (2011) Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection. J Virol 85:5513-23|
|Dreux, Marlene; Chisari, Francis V (2011) Impact of the autophagy machinery on hepatitis C virus infection. Viruses 3:1342-57|
|Montero, Ana; Gastaminza, Pablo; Law, Mansun et al. (2011) Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol 18:1453-62|
|Gastaminza, Pablo; Dryden, Kelly A; Boyd, Bryan et al. (2010) Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 84:10999-1009|
Showing the most recent 10 out of 12 publications